Access & pricing
Integrating insights and evidence to achieve optimal market access
Accelerate patient access to optimal healthcare through US and global market access and pricing strategies validated by the world's largest pre-vetted network of payers and KOLs.
Our market access and pricing consulting services include:
- RPR stakeholder engagement platform
- HTA landscapes
- Disease landscapes
- Pricing and reimbursement landscape
- Contracting/formulary decisions landscape
- Horizon scanning
- Briefing or strategic playbooks
- Target product profile (TPP) development and optimization
- Value message development
- Payer value proposition and hypothesis testing
- Objection handlers
- Value dossiers
- Stakeholder mapping
- Payer segmentation
- Therapy benchmarking/minimum required magnitude of benefit
- Advisory boards
- Strategy workshops
- Market access concept workshop with payers (e.g. IRA)
- Pricing strategy
- Innovative contracting strategy
Most-favored-nation pricing (MFN) continues to present complex strategic challenges. The GUARD and GLOBE models are highly nuanced and, in some areas, difficult to interpret; yet each carries significant implications for pricing, market access, and global launch strategy. Click below to access MFN expert-video updates and strategic insights through 2026.
Strategy. Insights. Access.
Discover our integrated, data-driven solutions for US and global access and pricing.
In today’s rapidly evolving environment, US and global access and pricing decisions demand robust evidence, rigorous analysis, and strategic precision.
We leverage our proprietary RPR stakeholder engagement platform, a network of 3,500+ vetted payers, clinicians, and KOLs across 65 countries, coupled with deep expertise in access, pricing, HEOR, and real-world analytics, to deliver end-to-end solutions that drive commercial success.
Our capabilities can be seamlessly integrated or applied independently—helping you transform complex challenges and gain a tangible competitive advantage throughout the product lifecycle.
Global strategic advisory
Navigate complex US and global challenges with clarity and confidence. Our experts partner with you to develop detailed strategies on product positioning, pricing, and value demonstration – maximizing commercial success through tailored, market-specific solutions.
Pricing strategy and analysis
We help you set and optimize the price of your product, considering the market dynamics, payer expectations, competitor activities, and regulatory requirements, and by assessing the impact of different pricing scenarios on your revenue and profitability.
RPR stakeholder insights
Empower strategic access and pricing decisions with RPR, our proprietary stakeholder engagement platform. Gain actionable and pressure-tested insights from 3,500+ vetted payers, clinicians, and KOLs across 65 countries – delivered faster and more robustly than traditional primary research methods.
Analogue and landscape research
Our tailored secondary research delivers precise benchmarking on pricing, reimbursement decisions, and HTA outcomes – seamlessly integrated with access and pricing, HEOR, and evidence generation expertise to reduce uncertainty and inform effective decision-making.
A&P Flexible Integrated Teams (FIT)
Benefit from adaptable contracting models tailored to your specific needs, or build an agile, extended partnership with our innovative Access & Pricing FIT (Flexible Integrated Team) for long-term strategic collaboration.
3500
stakeholders
65
countries
3
weeks to insights
Secure robust insights with our unique stakeholder engagement platform
Direct stakeholder engagement is critical when assessing your access and pricing strategy, insights, and messaging. Supported by our experts, our online RPR platform leverages a global network of 3,500+ vetted stakeholders across 65+ countries to secure robust insights in a fraction of the time and cost of a traditional approach.
Boosted
relevance
The RPR platform integrates real-world insights from decision-makers, enriching research findings and bridging data gaps to align with research goals.
Enhanced
accuracy
RPR not only fills research gaps but also refines insight. For instance, while secondary research might hint at a need for more RWE, RPR pinpoints the methodologies and outcomes acceptable to payers.
Superior
validity
RPR dives deeper than traditional research, sourcing data directly from key audiences, including payers, physicians, KOLs, and patient advocacy groups.
Strategic
decision-making
Manufacturers can fine-tune their market access and pricing strategies with RPR, enabling precise decision-making and clear identification of both risks and opportunities.
A global, vetted stakeholder network
3500+ experts across 65 countries are ready to provide the answers and clarifications you need
We search the globe for the most reputable experts before vetting them for suitability through a rigorous quality assurance and testing procedure. Each expert is tagged and classified according to their area of expertise and location, so that we can match the right experts to the right research objectives for our clients.
If you are an experienced healthcare decision-maker/stakeholder interested in helping to optimize patient outcomes, we invite you to consider sharing your expertise via our online survey platform, providing input when your schedule allows and being remunerated for your time.
Accelerated Insight Generation
Where technology meets market access expertise
Supported by specialist teams, our suite of agile technology platforms allows us to provide clients with enhanced pricing and market access services by delivering impactful insights at an accelerated rate.
Our RPR platform can be employed to integrate stakeholder insights into any aspect of product development and commercialization. EVID AI enhances and accelerates literature reviews; Dashboards leverage data visualization techniques to transform and extrapolate value from complex data into communicable insights; and our Integrated Evidence Planning platforms meet the challenge of evidence organization and communication.
It’s in our DNA. Discover your new strategic partner
Our strategic consulting framework provides a clear path from evidence to impact. We can provide you with a robust framework for strategic thinking, unbiased perspectives, clear next steps/rationale, and confidence in your decision-making.
Shining the light on vaccine market access
A World EPA Congress 2024 presentation with Katrin Nather, PhD, Associate Director, and Tijana Ignjatovic, Executive Director, Genesis Research Group.
With more and more innovative vaccines and immunization strategies coming to the market, there is an increasing drive for understanding the key decision drivers for vaccine market access. However, the overall decision-making processes across markets are often ill-defined.
Through our proprietary RPR platform, we have engaged with key decision stakeholders in vaccine market access to ‘shine a light’ on key decision criteria and access processes for vaccines in order to evaluate the opportunities of novel vaccines and guide strategic market access decisions.
Flexible Integrated Teams (FIT)
Market access research partnerships reimagined
Your access and pricing needs can be met through our optional FIT engagement model, an innovative approach which provides tailored, cross-functional RWE, HEOR, and market access teams that integrate seamlessly within your own to fill experience gaps or supplement existing resources.
The size and composition of your team can gradually evolve or pivot quickly to meet your changing needs, all without the costly delays involved in adjusting a statement of work.
A trusted extension of your organization, our team becomes your team.
Selected access and pricing publications
Our teams have co-authored over 1000 publications across the full range of therapeutic areas, data sources, indications, and methods. A selection of our recent access and pricing related publications can be found below. For a wider list, please visit our publications directory.
| Title | GR Author(s) | Year | Therapeutic Area | Data Source | Journal/Conference | Full Citation & Links |
|---|---|---|---|---|---|---|
| Assessment of the relevance and credibility of indirect treatment comparisons to help inform health technology assessment and reimbursement decision-making: results of a 5-country payer survey. | Katsoulis I, Graham A | 2023 | General Medicine | RPR Survey | ISPOR Europe | View |
| Paradigm Shift or Incremental Change? Real-World Evidence for Health Technology Assessment in Oncology. | Ignjatovic T | 2023 | Oncology | RPR Survey | ISPOR Europe | View |
Genesis Research Hub
Headquarters:
HOBOKEN
111 River Street, Suite 1120
Hoboken, New Jersey 07030, US
